Business Wire

Pricefx Launches Industry’s First AI-powered Market Simulation for Price Optimization

27.4.2021 16:30:00 EEST | Business Wire | Press release

Share

Pricefx, the global leader in cloud-native pricing software, today announced it has released the industry’s first AI-powered market simulation solution. Market simulation is designed to enable price optimization in context of the overall product portfolio and the competition. It uses Pricefx Next Gen AI technology to simulate and predict the impact of pricing on customer purchasing behavior. As a result, businesses can make better business decisions – informed by predicted impact – to accelerate profit growth.

Leveraging AI optimization, Pricefx provides businesses a simulated response to various “what if” scenarios. Market simulation evaluates a range of products, the impact on volumes and optimizes pricing for the full portfolio. It simulates the impact of price change to a product on the surrounding products within the business’ own portfolio to identify potential market cannibalization. It predicts real behavior of customers and competitors by simulating the market response to price changes and demonstrates the long-term market impact including market share changes.

McKinsey's Global AI Survey found that 40% of marketing and sales departments using AI achieve 6% or higher average revenue growth. In marketing and sales, respondents most often report revenue increases from AI use in pricing, prediction of likelihood to buy, and customer-service analytics. AI is credited with improving the accuracy, scale and speed of price optimization and business leaders report that adopting AI-based price optimization is among the best decisions they made before and during the pandemic to protect margins and resist descending into price wars. McKinsey forecasts that AI-based price and promotion have the potential to deliver between $259.1 billion to $500 billion in global market value.

“Market simulation is the next evolution of price optimization,” said Toby Davidson, Chief Product Officer for Pricefx. “AI-powered price optimization is improving business' viability, driving more revenue and accelerating profit growth. By adding AI-based market simulation, Pricefx continues to deliver real solutions for our customers’ business challenges. We are extending our leadership position in pricing optimization to deliver new and powerful profitability tools to our customers, with the same fast, flexible and friendly approach they have come to expect.”

Under the newly redesigned Plan, Price and Profit solution sets, Pricefx includes market simulation for subscribers of its Price and Profit packages. The Pricefx Price package provides customers with a comprehensive set of price management tools. It leverages AI-powered price optimization to fine-tune all pricing elements simultaneously with speed and accuracy. The Pricefx Profit package empowers sales teams to autonomously and efficiently handle sales inquiries at a granular level while reaching the best deal outputs to increase profit. It contains an industry-only CPQ with integrated Value Estimation features, coupled with the industry’s leading large deal negotiation and deal management workflow solution.

Additional resources

Blog: https://www.pricefx.com/learning-center/bijou-next-gen-price-optimization-market-simulation
LinkedIn: https://www.linkedin.com/company/price-f-x-/
Twitter: https://twitter.com/price_fx

About Pricefx

Pricefx is the global leader in SaaS pricing software, offering a comprehensive suite of solutions that are fast to implement, flexible to configure and customize, and friendly to learn and use. Based on cloud-native architecture, Pricefx delivers a complete price optimization and management platform that provides the industry’s fastest time-to-value and lowest total cost of ownership. Its innovative solution works for B2B and B2C enterprises of any size, in any industry, in any part of the world. Pricefx’s business model is entirely based on the satisfaction and loyalty of its customers. For enterprises facing pricing challenges, Pricefx is the cloud pricing optimization, management, and CPQ platform to dynamically Plan, Price and Profit.

For more information, please visit www.pricefx.com.

###

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Cathy Summers
Summers PR for Pricefx
cathy@summers-pr.com
+1 (415) 483-0480

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces Positive CHMP Opinion for Opzelura ® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 14:30:00 EEST | Press release

Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs) are inadequate or inappropriate. “AD is a chronic skin condition that can have a significant impact on daily life. The positive CHMP opinion for Opzelura marks meaningful progress toward bringing the first non-steroidal topical JAK treatment option to adults in Europe with moderate AD for whom standard topical therapies have failed,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved by the European Commission, Opzelura could help address an important gap for patients who have limited treatment options when TCSs and TCIs are inadequate or inappropriate.” The positive CHMP o

Datroway ® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 14:00:00 EEST | Press release

Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the TROPION-Breast02phase 3 trial, which werepresented at the 2025 European Society for Medical Oncology Congress and published in Annals of Oncology. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In TROPION-Breast02, Datroway demonstrated a

DAYBU ® (trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 13:49:00 EEST | Press release

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating condition," said Catherine Owen Adams, Acadia’s Chief Executive Officer. “Our commitment is to make a meaningful difference in the lives of patients, caregivers, and the wider Rett com

HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 12:18:00 EEST | Press release

HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi

Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 11:28:00 EEST | Press release

Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye